Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 37Unknown 11Recruiting 7Terminated 4Active not recruiting 3Withdrawn 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 120Neoplasms 75Prostatic Neoplasms 70Lung Neoplasms 36Carcinoma, Non-Small-Cell Lung 33Pancreatic Neoplasms 32Colorectal Neoplasms 32Head and Neck Neoplasms 29Carcinoma, Hepatocellular 24Brain Neoplasms 24Colonic Neoplasms 22Motor Activity 19Carcinoma, Renal Cell 18Pain 16Ovarian Neoplasms 16Neoplasm Metastasis 14Hematologic Neoplasms 14Urinary Bladder Neoplasms 13Rectal Neoplasms 13Lymphoma, Follicular 13Fatigue 13Sarcoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Glioblastoma 12Lymphoma 11Liver Neoplasms 11Glioma 11Squamous Cell Carcinoma of Head and Neck 10Leukemia 10Anxiety Disorders 10

Interventions

Office Visits 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Withdrawn × Uterine Neoplasms × Clear all
NCT04368130 2022-10-14

SIGNAL

Dana-Farber Cancer Institute

Phase NA Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT03583736 2020-06-30

Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer

Case Comprehensive Cancer Center

Phase NA Withdrawn
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡